1801 — Innovent Biologics Cashflow Statement
0.000.00%
- HK$66.02bn
- HK$59.02bn
- CNY6.21bn
Annual cashflow statement for Innovent Biologics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1,720 | -859 | -3,051 | -2,170 | -1,144 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 96.6 | 939 | 938 | -312 | 389 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -128 | -474 | -117 | 244 | 518 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -1,664 | -308 | -2,025 | -1,919 | 148 |
Capital Expenditures | -366 | -522 | -1,848 | -1,366 | -1,382 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -2,203 | -4,663 | -851 | -69.7 | 383 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -2,569 | -5,185 | -2,698 | -1,435 | -999 |
Financing Cash Flow Items | -89.2 | -88.6 | -132 | 73.6 | -54.6 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 2,109 | 4,912 | 5,003 | 2,892 | 2,587 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2,099 | -1,150 | 83.2 | -343 | 1,730 |